RT Journal Article
SR Electronic
A1 Mares, Jan
A1 Hartung, Hans-Peter
T1 Multiple sclerosis and COVID-19
JF Biomedical papers
YR 2020
VO 164
IS 3
SP 217
OP 225
DO 10.5507/bp.2020.033
UL https://biomed.papers.upol.cz/artkey/bio-202003-0001.php
AB This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).